Combining ARPIs With Radionuclide Therapy Tied to Better Survival in Metastatic CRPC

(MedPage Today) -- A secondary analysis of the phase III VISION trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway inhibitors (ARPIs) to ¹...